Business Wire

Crown Bioscience Expands UK Facilities to Enable Growth of In Vivo Services

Share

Crown Bioscience, a JSR Life Sciences company and leading contract research organization (CRO) in preclinical and translational drug development services, today announced that it has completed the expansion and renovation of its Crown Bioscience United Kingdom facility. The additional laboratory and office space will increase capacity and expand the company’s current in vivo offering by 30 percent and provide dedicated space for a newly acquired high frequency ultrasound unit – a specialized high-resolution imaging device designed to increase the utility of two- and three-dimensional imaging without the need for cell line-tagging, coupled with high precision guided inoculation/dosing of orthotopic and metastatic models.

“This expansion is a critical step in our ability to provide additional imaging modalities to better visualize and understand tumor progression and response to potential therapies,” said Yinfei Yin, PhD, General Manager at Crown Bioscience UK. “This additional imaging platform allows us to perform cutting-edge preclinical studies, offering our customers advanced insights on potential drug candidates before they enter clinical trials.”

The Company’s UK site leverages more than 15 years of experience in in vivo optical imaging, including bioluminescence, fluorescence and microCT modalities. Specifically, the addition of high frequency ultrasound will enable better longitudinal evaluation of tumor growth and earlier, more detailed analytics on the tumor microenvironment.

“This site expansion is driven by increased customer demand for access to Crown Bioscience’s in vivo services from the UK and mainland Europe, and allows us to build upon our innovative foundation to develop additional industry-leading technologies,” said Armin Spura, PhD, Chief Executive Officer of Crown Bioscience. “Following our recent acquisition of OcellO B.V. and launch of our 3D Ex Vivo Patient Tissue Platform, this milestone enables Crown Bioscience to continue to use the power of partnership to unlock breakthroughs in drug discovery and, ultimately, to provide patients with better treatment options.”

Crown Bioscience UK serves customers advancing preclinical and clinical oncology and immuno-oncology studies. The site offers a comprehensive suite of in vivo models, including PDX, CDX and syngeneic portfolios incorporating orthotopic, metastatic, and systemic variations, as well as in vitro and ex vivo services, such as cell viability, invasion/migration assays, immunoassays, 3D-TGA and combination studies/analysis.

About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: www.crownbio.com.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries
Laura Morgan
Sam Brown Inc.
LauraMorgan@sambrown.com 
+1 951-333-911 

Company Inquiries
Louise Stenson
Crown Bioscience
louise.stenson@crownbio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westmount Realty Capital Recapitalizes 6.1 Million Square-Foot Industrial Portfolio in Chicago and Milwaukee26.1.2022 21:33:00 EET | Press release

Westmount Realty Capital, a privately held, Dallas-based commercial real estate company announced today that it is partnering with a fund managed by the Real Estate Group of Ares Management Corporation, a leading global alternative investment manager, to recapitalize a 51-asset industrial portfolio totaling 6.1 million square feet located in established industrial submarkets of Chicago and Milwaukee. Westmount and Ares acquired the institutional-quality portfolio of logistics, bulk distribution, and last-mile industrial properties from a Partners Group Westmount joint venture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005816/en/ Westmount Realty Capital and Ares Management Corporation recapitalized and acquired an institutional-quality portfolio of logistics, bulk distribution, and last-mile industrial properties totaling 6.1 million square feet located in established industrial submarkets of Chicago and Milwaukee

artnet AG: Artnet Joins New Deutsche Börse ESG Visibility Hub26.1.2022 20:25:00 EET | Press release

Artnet AG, the leading platform for art market data and media, and the global marketplace for fine art online-only sales, is pleased to announce that it has joined the new Deutsche Börse ESG Visibility Hub. Investors increasingly expect transparency from companies with regard to sustainability. A high level of disclosure and comprehensible reporting enables ESG-related data (ESG translates to Environment, Society, Governance) to be included in investment decisions - with the aim of lowering the risks and positive impact of an investment. Artnet AG has been a pioneer within the art market for over 30 years. By engaging with ESG reporting and initiatives, Artnet continues its ethos of spearheading positive change and sustainable business practices. Artnet strives to continuously offer an environment where its employees, customers, and stakeholders can do what they love in a sustainable way. Furthermore, Artnet values its role in assisting clients in engaging with fine art and collectible

VitreaLab, Quantopticon, Luminess Win Big at SPIE Startup Challenge26.1.2022 19:35:00 EET | Press release

Yesterday, at a ceremony during SPIE Photonics West, VitreaLab, with its laser-lit chip focused on the 2D and 3D display market – a technology which enables more power-efficient displays – was announced the winner of the $10,000 top prize at the 12th annual SPIE Startup Challenge. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005652/en/ Jonas Zeuner of VitreaLab, center, is joined onstage by Jenoptik's Song Yop Chung, left, and Ralf Kuschnereit, right. (Photo: Business Wire) With cash prizes all provided by Jenoptik, Quantopticon, a designer of simulation software for quantum photonic hardware manufacturers, received $5,000 for second place. Luminess came in third, winning $2,500, with their versatile platform for safer, more sensitive, and more reliable X-ray medical imaging. The SPIE Startup Challenge, which showcases new businesses, products, and technologies that address critical needs with photonics, is supported

ABO - Óskare Capital: Partnership Announcement26.1.2022 17:30:00 EET | Press release

Alpha Blue Ocean (ABO) and Óskare Capital are announcing today the formation of a strategic partnership to collaborate on investment opportunities associated with cannabis plant-based medicines as well as synthetic molecules that target the mammalian Endocannabinoid system (ECS). Both companies recognize that there are also investment opportunities related to products, infrastructure technologies and services which will be part of the associated ecosystem for this sector. With a strong focus in Europe, the teams will work together to identify those companies with the greatest potential to enter global markets. This sector is nascent in Europe and is still in early stages of development on the pharmaceutical side; both companies see this as a “blue ocean” opportunity as the market emerges in the years to come. The partnership is based on biotech, agtech, and life science expertise; track records in the European VC; and strong access to deal flow, all of which will enable the partnership

Staffmark Group Leverages Rimini Street Support for Oracle PeopleSoft Powering Payroll for 35,000 Employees a Week26.1.2022 17:00:00 EET | Press release

Rimini Street, Inc. (NASDAQ: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Staffmark Group, an award-winning staffing and recruitment firm, continues to leverage Rimini Street to support the company’s PeopleSoft system environment support and maintenance. Since making the switch to Rimini Street, Staffmark has significantly improved the quality, responsiveness and depth of PeopleSoft support available to its internal IT team, enabled faster tax, legal and regulatory updates, and plans to reinvest support cost savings in service offering innovation and enhancements such as AI analysis capabilities and automated job posting functionality for employers and jobseekers – a vital part of its competitive market strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005280/en/

Covetrus Taps César França as President, Global Proprietary Brands26.1.2022 17:00:00 EET | Press release

Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of César França as President, Global Proprietary Brands. França will lead the companywide development and management of Covetrus’ global proprietary brand portfolio, including the current Covetrus, Kruuse, Vi, Roadrunner Pharmacy, and Calibra brands. The company will rely on his vision and expertise to develop categories, build strategic partnerships, and identify external growth opportunities. França brings more than 25 years of leadership and experience in brand development and management, marketing, sales, business development, and general management to Covetrus. “We’re delighted to welcome César to this new and dynamic role,” said Matt Malenfant, Chief Commercial Officer at Covetrus. “César is a positive, trusted leader with a foundational belief in the power of people and brands. He will work closely with our commercial and operations teams to ensure effectiveness an

o9 Solutions Raises $295 Million From Strategic Investors to Continue its Growth Across Industry Verticals & Markets26.1.2022 16:00:00 EET | Press release

o9 Solutions, a leading enterprise AI software platform provider for transforming planning and decision-making speed and quality in companies across industry verticals, today announced that it has received equity investments totaling $295 million from General Atlantic, including BeyondNetZero, its climate investing venture, Generation Investment Management, a pure-play sustainability investment manager, and existing investor KKR. This significant investment will help o9 build on its momentum and accelerate growth for its AI-powered Integrated Business Planning platform it calls the “Digital Brain” across industry verticals and markets. It will also help o9 drive continued innovation in R&D, industry knowledge models and partner ecosystem development that will help companies implement o9’s game-changing platform faster and realize greater value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005218/en/ Chakri Gottemukka

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom